A phase I study of an adenoviral vector delivering a MUC1/CD40-ligand fusion protein in patients with advanced adenocarcinoma
oleh: Tira J. Tan, W. X. Gladys Ang, Who-Whong Wang, Hui-Shan Chong, Sze Huey Tan, Rachael Cheong, John Whay-Kuang Chia, Nicholas L. Syn, Wai Ho Shuen, Rebecca Ba, Nivashini Kaliaperumal, Bijin Au, Richard Hopkins, Xinhua Li, Aaron C. Tan, Amanda O. L. Seet, John E. Connolly, Thaschawee Arkachaisri, Valerie Chew, Ahmad bin Mohamed Lajam, Dianyan Guo, Marvin Z. W. Chew, Martin Wasser, Pavanish Kumar, Salvatore Albani, Han Chong Toh
| Format: | Article |
|---|---|
| Diterbitkan: | Nature Portfolio 2022-10-01 |
Deskripsi
Ad-sig-hMUC1/ecdCD40L is a recombinant adenovirus vaccine comprising human MUC1 antigen fused to the extracellular domain of the CD40 ligand. Here the authors report the result of a phase I clinical trial of Ad-sig-hMUC1/ecdCD40L in patients with advanced adenocarcinoma.